NCT02600117View on ClinicalTrials.gov

Use of TDF in Patients With Inactive Chronic Hepatitis B Infection

PHASE3CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Tenofovir disoproxil fumarate

300 mg, oral, once a day

Trial Locations (1)

M5G 2C4

University Health Network - Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

University Health Network, Toronto

OTHER